A single vaccination of mice with a complex of porin and smooth lipopolysaccharide (porin-S-LPS) extracted from yirulent Brucella abortus 2308 provided significant protection (P < 0.01 to P < 0.001) against challenge with the same strain, equivalent to that achieved by vaccination with living attenuated B. abortus 19. The porin-S-LPS vaccine given without adjuvant or in several adjuvants (trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes) provided equivalent protection. In contrast, one vaccination with porin complexed with rough LPS (porin-R-LPS) from a rough mutant of strain 2308 provided no protection with any adjuvant tested. In one experiment, two inoculations with the porin-R-LPS resulted in a low level of protection, probably owing to priming of the animals for production of O-polysaccharide-specific antibodies. However, one vaccination with rough-strain porin covalently bound to purified 0 polysaccharide conferred protection equal to that obtained with natural complexes of porin-S-LPS or with living strain 19. A synthetic vaccine containing long chains of 0 polysaccharide was more effective than one prepared with short chains. Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative associatiQn between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice. These results provide additional evidence that the 0 polysaccharide will constitute an essential component of an effective subcellular vaccine against B. abortus and that O-polysaccharide-specific antibodies play an important role in protective imnmunity in brucellosis.
Disease caused by Brucella abortus affects humans and a number of animal species, particularly cattle (43) . Attenuated B. abortus 19 has been used for many years to vaccinate cattle against brucellosis. Among the major drawbacks of this vaccine are its ability to cause disease in cattle (14) and humans (56) and to induce O-polysaccharide (OPS)-specific antibodies (O antibodies) which interfere with the interpretation of serodiagnostic tests (43) .
A principal goal of research in this laboratory (31, (53) (54) (55) and others (5, 6, 13, 15, 47, 48) is the development of a subcellular vaccine for bovine brucellosis. Such a vaccine would not be commercially acceptable unless it provided an advantage over strain 19 such that the antibody response which it induced could be clearly distinguished from that evoked by virulent field strains. This could be accomplished easily if it was possible to design an effective vaccine which excluded the OPS. However, recent studies with the murine model system have provided evidence by active (31) and passive (26, 31, 32) This question must be resolved to provide direction for future efforts on development of subcellular vaccines. The experiments reported here were done in pursuit of that objective. We performed active immunizations with simple and defined vaccines with or without the OPS. The design of the experiments was based on a hypothesis proposed by one strain 2308 and rough strain NADC by a modification of previously described methods (51) . Porins were freed of detergents, lyophilized, and stored in a desiccator at room temperature (55) . Porin from rough strain RB51, which was used for production of synthetic vaccines, was produced by a modification of the methods of Verstreate et al. (51) in which bacterial cells were disrupted by vortexing with glass beads for 5 min at 0°C (Bead-Beater; Biospec Products, Bartlesville, Okla.) and proteins separated by ion-exchange chromatography were subjected to chromatofocusing (PBE 94; Pharmacia Fine Chemicals, Inc., Piscataway, N.J.) prior to gel filtration. Denaturation of the porin was required for successful coupling to the OPS. This was accomplished by heating the protein at 100°C for 15 min in 10 mM Tris buffer (pH 8.0) containing 0.1 M NaCI, 0.1% Zwittergent 3-14 (Calbiochem-Behring, La Jolla, Calif.), 0.02% NaN3, and 2% sodium dodecyl sulfate. Sodium dodecyl sulfate and NaN3
were removed by gel filtration on Sephacryl S-300 (Pharmacia) equilibrated with 50 mM phosphate buffer (pH 7.5) containing 0.1 M NaCl and 0.015% Zwittergent 3-14. Porincontaining fractions were pooled and concentrated by ultrafiltration during which the buffer was replaced with carbonate buffer (0.1 M, pH 9.2) used in the coupling reaction.
(ii) S-LPS. S-LPS (fraction f6) was produced from smooth strain 2308 by extraction in hot phenol followed by treatment with guanidinium thiocyanate (38) .
(iii) OPS. LPS was extracted from cells of B. abortus smooth strain 2308 by the method of Moreno et al. (35) . A solution of purified LPS in 2% acetic acid was refluxed at 100°C (8 h), cooled to 4°C, and diluted with an equal volume of 70% trichloroacetic acid to precipitate proteins. After centrifugation (17,000 x g, 15 min), the supernatant was combined with methanol (5 volumes) at 4°C, stirred (16 h) , and centrifuged (17,000 x g, 20 min). The resulting pellet was dissolved in distilled deionized water (DDW) (100 ml), dialyzed against DDW for 2 days, and lyophilized. The product was suspended in 20 mM Tris chloride buffer (pH 8.0, 100 ml) and centrifuged (17,000 x g, 10 min), and the supernatant was applied to a column of DEAE-Sephadex A-50 equilibrated with the same buffer. Eluted fractions (absorbing at 210 nm) were combined, and OPS was precipitated by the addition of 5 volumes of methanol at 4°C. After centrifugation (17, 000 x g, 15 min), the pellet was dissolved in DDW, dialyzed against DDW, and lyophilized, affording pure OPS whose 13C and 'H nuclear magnetic resonance and infrared spectra were in agreement with published values (10) .
(iv) Preparation of long and short OPS oligomers. Anhydrous HF (15 ml) was added to a 2-oz (59-ml) polyethylene bottle with a Teflon stir bar under argon charged with 775 mg of purified OPS. The bottle was tightly capped, and the colorless solution was stirred at -20°C for 2.5 h. The HF was removed under anhydrous conditions with a stream of argon and then under vacuum (0.1 torr [13.33 Pa] , minimum 1 h) until the reddish solid became colorless. This residue was dissolved in DDW (10 ml) and submitted to gel filtration on a column (2.6 by 95 cm) of Bio-Gel P-4 (200/400 mesh) at a flow rate of 10 mI/h and with UV detection at 210 nm. Fractions were collected at ca. 190 to 200 ml (void volume), ca. 200 to 300 ml, and ca. 300 to 400 ml to afford, after lyophilization, unreacted OPS (42 mg, 6%), long a-1-fluoro-OPS oligomers (306 mg, 41%), and short ot-1-fluoro-OPS oligomers (214 mg, 28%), respectively. Short-chain oligomers were calculated to contain between 5 and 20 sugar residues, while the size of long-chain oligomers varied from about 20 sugar residues to native length.
Long (382 mg) and short (219 mg) a-1-fluoro-OPS oligomers were suspended in 2.6 and 1.4 ml, respectively, of freshly distilled 2-azidoethanol. (It must be emphasized that 2-azidoethanol is explosive. Preparations of this material should never be heated above 60°C, and all distillations must be performed behind a safety shield.) Additional 2-azidoethanol (2.6 and 1.4 ml, respectively) saturated with anhydrous HCI was added to each vessel. After being capped tightly, the solutions were stirred at 25°C for 12 h. Hydrogen chloride was removed in vacuo at 20°C and residual 2-azidoethanol was removed under vacuum (0.1 torr) at 25°C over ca. 24 h. Each crude product was dissolved in ca. 5 ml of DDW and applied to a Bio-Gel P-4 column (2.6 x 95 cm) (200/400 mesh) with a flow rate of ca. 8 ml/h. Lyophilization afforded long azidoethyl-OPS (300 mg, 79%) and short azidoethyl-OPS (200 mg, 91%).
Catalytic hydrogenation of the long (317 mg) and short (324 mg) azidoethyl-OPS was done in separate 100-ml roundbottom flasks by adding 10% Pd on C (150 mg) to solutions of each sample in ethanol-water (75 ml:15 ml). The mixtures were stirred while H2 was bubbled through E-fritted tubes for 36 to 48 h. Ethanol was removed in vacuo and was replaced by 100 ml DDW. Catalyst was removed by filtration through a 4-mm pad of Celite, and the solutions were lyophilized to afford both long 2-aminoethyl-OPS (286 mg, 90%) and short 2-aminoethyl-OPS (260 mg, 80%).
A 100-mg sample of either long or short 2-aminoethyl-OPS in DDW (2.5 ml) was added to a solution of di-2-hydroxypyridyl thionocarbonate (23) (TDM) and N-acetylmuramyl-L-co-aminobutyryl-D-isogliutamine (bMDP) were preparations used previously (31) . Preparation of vaccines with these adjuvants was as described previously (31) except that squalane (Sigmna Chemical Co., St. Louis, Mo.) was used in place of mineral oil.
(ii) ISCOMs. Immunostimulating complexes (ISCOMs) were prepared by published methods by Morein and colleagues (34, 45) with porins of the smooth and the NADC rough strain of B. abortus 2308.
(iii) L-121 and MDP. The method of vaccine preparation for L-121 and MDP was kept as similar as possible to that used for TDM and MDP. bMDP solubilized in methanol was added to dried antigen in a glass homogenizer. After the methanol was completely evaporated, the pluronic polyol L-121 (20, 21) (BASF Wyandotte, Co., Parsippany, N.J.) and squalane were added and homogenized as previously described (55) The kinetics-based ELISA was used because it enables more precise comparisons to be made among samples (22) . For ease of understanding, however, the approximate conversions of the data from slope values to titers are included in the tables and will be used in referring to antibody responses. To obtain these conversions, we prepared samples from a positive control serum which gave titers of 50 a S-LPS fraction of f6 was used as a standard. Calculations were based on the content of S-LPS and OPS in the f6 sample as 94% (35, 38) and 67% (35) , respectively.
b Native porin from smooth strain 2308. Native porin from rough 2308 strains NADC and RB51. d Short-or long-chain OPS covalently linked to denatured porin from strain RB51.
procedures were as described above. Duplicate external dilutions of 100-,lI samples of test antigen were incubated with 100 RI of a 1:800 dilution of monoclonal antibody for 3 h prior to the addition of 100 jil of the mixture to a washed antigen-coated well for 1 h. After washing, 100 ,u of alkaline phosphatase-conjugated goat anti-mouse immunoglobulin G (Organon Teknika) was added for a 3-h incubation. After washing, 100 pul of p-nitrophenyl disodium phosphate was added at 1 mg/ml in diethanolamine buffer (pH 9.8), and slope values were determined from readings at 405 nm 2, 4, and 6 min later. A standard curve was prepared with samples of f6 in twofold dilutions from 20 to 0.31 jg. Test samples were assayed at concentrations of 40, 20, and 10 jig. An equation for the standard curve was determined by linear regression and then used to calculate the concentration of OPS in the test samples. An r2 of 0.97 was found for the regression after log transformation of the antigen concentrations. The f6 standard was assumed to contain 94% S-LPS (35, 38) and 67% OPS (35) .
Statistical methods. A log value of bacteria in each spleen was obtained by averaging the triplicate counts following log conversion (31) . Statistical significance was determined by Fisher's protected least-significant-difference test (42) . Correlations were analyzed by Pearson's product moment test (42) . RESULTS OPS content of antigens. Porin extracted from smooth strain 2308 contained an estimated 15% associated S-LPS (Table 1) , consistent with prior data (51). The two preparations of porin derived from rough strains of 2308 contained trace quantities of S-LPS according to the competitive inhibition assay (Table 1) Table 2 ). The magnitude of protection was not significantly enhanced at either time period by the inclusion of TDM and MDP adjuvant in the vaccine. In contrast, vaccination with the same quantity of porin-R-LPS with or without adjuvant provided no significant protection against either challenge strain (Table 2) .
Vaccination trials with porins incorporated into ISCOMs produced the same results. Porin-S-LPS ISCOMs provided significant protection against strain 2308 at 1 and 4 weeks p.i. even at the lowest dose tested (40 ng) ( Table 3) . At 1 week p.i., protection provided by 30 jig of porin-S-LPS in PBS was not different from that produced by 5 jig of ISCOMs, but was significantly greater (P < 0.001 to P < 0.01) than protection provided by all lower doses. Decreasing doses of ISCOMs produced successively lower levels of protection (Table 3 ) which were significantly different from each other (P < 0.001 to P < 0.05) except for the 1-jig and 200-ng doses. At 4 weeks p.i., no significant differences in protection could be ascribed to dose of vaccine or presence of adjuvant. Again, porin-R-LPS in ISCOMs produced no significant protection at any dose used (Table 3 ).
An experiment was next performed to test the effect of different adjuvants in enhancing protection provided by a uniform dose of porin-S-LPS. A 5-jig dose of porin-S-LPS conferred significant protection against strain 2308 at 1 and 4 weeks p.i. whether given as ISCOMs, with TDM and MDP, with L-121 and MDP, or without adjuvant ( Vaccination trials with synthetic complexes of porin and OPS. The results obtained with natural complexes of porin and LPS supported the hypothesis that the OPS was an essential component of an effective vaccine. We therefore proceeded to determine whether porin-R-LPS, an ineffective vaccine, could be converted into an effective one by the addition of OPS.
In the first experiment, mice were vaccinated with 30 ,ug of synthetic complexes of R-porin coupled with long (R-porin-OPS-long) or short (R-porin-OPS-short) chains of OPS in the TDM and MDP adjuvant. The synthetic complexes conferred significant protection against challenge infection with strain 2308 at 1 week p.i. (P < 0.001) ( Table 5) . Protection was comparable to that obtained in mice vaccinated with porin-S-LPS (Table 5 ) and was significantly greater than that due to adjuvant alone (Table 5) (P < 0.001). Mice vaccinated with porin-R-LPS were not protected (Table 5) . In another trial, protection was demonstrated at 1 week (P < 0.001) and 4 weeks (P < 0.05) in mice vaccinated with 30 ,ug of R-porin-OPS-long without adjuvant, whereas no protection was afforded to mice vaccinated with the same lot of denatured porin which had not been conjugated to OPS (Table 6) .
Despite initial success achieved with the R-porin-OPS short-chain vaccine (Table 5) , two attempts to reproduce protection with this preparation failed (data not shown). An experiment was therefore performed to determine whether revaccination would improve the effectiveness of this vaccine. At the same time, a direct comparison was made between the natural and synthetic porin vaccines and living strain 19 . Mice vaccinated twice with porin-S-LPS or Rporin complexed with either long-or short-chain OPS were protected following challenge with strain 2308 (P < 0.01 to P < 0.001) ( Table 7) . Levels of protection obtained with the subcellular vaccines were in no instance significantly different from that achieved with strain 19. In this experiment, low (0.74 logs) but significant (P < 0.05) protection was also achieved with the porin-R-LPS vaccine (Table 7) . Protection achieved with the porin-R-LPS vaccine was, however, significantly below that obtained with strain 19, porin-S-LPS, or R-porin-OPS-long vaccines (P < 0.01).
Association of protection with induction of 0 antibodies. Pooled sera taken just prior to challenge infection from mice vaccinated 4 weeks earlier with 5 ,ug of porin-S-LPS in PBS contained 0 antibodies at a titer of 100, and incorporation of adjuvants increased the titers four-to eightfold (Table 4 ). All these vaccines conferred high levels of protection, as noted above (Table 4) .
In the experiment reported in Table 7 , pooled sera were collected from each group prior to the first and second vaccinations and prior to challenge infection. Individual samples were taken prior to killing the mice at 1 week p.i. A single vaccination with porin-S-LPS resulted in a titer of 0 antibodies of 200 4 weeks later (Table 7) . This was increased to 800 as a result of revaccination and remained at this level Mice were bled retro-orbitally prior to challenge. Pooled serum samples were tested in kinetics-based ELISA against fraction f6. Numbers reported are slopes, and titers were estimated from slopes (Fig. 1). INFECT. IMMUN. after challenge infection (Table 7) . Although vaccination with porin-R-LPS produced only the most marginal increase after the second inoculation, it is notable that the titer in this group following challenge was fourfold greater than that in the nonvaccinated group (Table 7) . In contrast with the high antibody response (titer of 400) observed after the first vaccination with the synthetic long-chain vaccine, a single vaccination with the short-chain vaccine produced no increase in 0 antibodies (Table 7) . A second inoculation of the short-chain vaccine caused the appearance of circulating 0 antibodies (titer of 100), and the titer of antibodies in this group following challenge was fourfold greater than that in the nonvaccinated group (Table 7) . Antibody levels (measured as slope values) at 42 days were correlated in an inverse fashion with mean log numbers of bacteria cultured from the spleens of each treatment group (r2 = -0.828; P < 0.05).
Marginal increases in antibodies specific for the porin-R-LPS complex were detected in groups immunized with subcellular vaccines (Table 7) . In only one instance did these attain a titer of 25 (Table 7) .
Further analyses were performed on individual sera of four of the groups to determine whether levels of 0 antibodies at 1 week p.i. were correlated with protection in individual animals. For this purpose, the 0 glycolipid was used as the antigen, primarily to ensure that antibody responses produced by porin-R-LPS were not directed against porin or lipid A determinants. Analyses of the 35-day and 42-day serum pools with f6 and 0 glycolipid antigens demonstrated comparable reactions (Table 8 ) which were highly correlated (r2 = 0.968; P < 0.01). Slopes of reactions against 0 glycolipid were on the average 12.5% lower than those with f6. Levels of 0 antibodies were very similar in mice numbers 13 to 18, immunized with the long-chain synthetic vaccine, in which spleen counts showed little variation ( Table 9 ). In the other groups, selected because of the higher standard deviations in spleen counts, a range of antibody levels occurred within each group and in no group was there a significant correlation between antibody levels and spleen counts. In a few animals (numbers 4 and 19), high levels of protection occurred despite levels of 0 antibodies no different from the mean level in the nonvaccinated controls (Tables 7 and 9 ). DISCUSSION B. abortus is a facultative intracellular parasite (11, 28) , and evidence from the murine model of infection indicates that humoral (3, 26, 29, 32, 36, 39, 44) as well as cellmediated (31, 37, 40) immune responses contribute to protection. The same views are currently held in respect to immunity against Salmonella typhimurium (16) . In murine infections with both B. abortus (26, 32) and S. typhimurium (12) , monoclonal antibodies specific for the OPS have been shown to confer protection passively. The data presented here complement and extend these findings with B. abortus by demonstrating that an acquired immune response to the OPS provides protection equivalent to that obtained with a living vaccine (Tables 7 and 9 ). It must be emphasized in this connection that in the model system we used, critical comparisons in logs of protection (i.e., the difference in mean log numbers of brucellae in the spleens of vaccinated and control groups) achieved by various vaccines must be restricted to comparisons made within the same experiment. For example, in experiments performed 15 months apart which are reported in Tables 3 and 7 , vaccination of mice with 30 ,ug of the same preparation of porin-S-LPS in PBS produced logs of protection at 1 week p.i. of 3.33 and 1.74, respectively. Each result reflected a highly significant difference from control values (P < 0.001). Different lots of challenge strain 2308 were used in the two experiments. Small differences in lots of B. abortus challenge strains and in lots of experimental animals probably account for most of these variations. We have also noted that protection achieved at 1 week p.i. is a reliable predictor of protection at later time intervals. With infrequent exceptions, protection following vaccination with either living strain 19 or subcellular vaccines decreases between 1 and 4 weeks p.i. (Tables  2, 3 The synthetic vaccine which contained long OPS chains proved better than the one with short OPS chains. This was associated in the long-chain vaccine with a higher apparent content of OPS (Table 1) (25) 10 (<) Porin-R-LPSe (30) f6 2 (<) 4 (K) 9 (K) 117 (200) 5.66 ± 0.87* Porin-R-LPS 4 (K) 5 (K) 9 (K) 13 (<) R-porin-OPS (longf (30) The weight of evidence supports the view that protection induced by the subcellular vaccines resulted from the induction of 0 antibodies. In the first instance, highly effective protection could be induced without the requirement for adjuvants which enhance cell-mediated immune responses (Tables 2, 3 , 4, 6, and 7). Second, antibodies specific for moieties other than the OPS (e.g., porin, lipid A, or LPS core epitopes) were found in extremely low concentrations in sera of immune mice (Table 7) . Third, there was a proportional relationship between the capacity of a vaccine to induce 0 antibodies and its capacity to induce protective immunity. This was evident in assays performed both before (Tables 4, 7 , and 8) and after (Tables 7 and 8) aSerum pools tested were from the same experiment reported in Table 7 .
b Slope values from kinetics-based ELISA.
( Table 9 , mice 4 and 19) and others in which protection was marginal or absent despite raised levels of 0 antibodies (Table 9 , mice 6, 10, 11, 12, and 24). Such exceptions do not, however, invalidate the hypothesis that 0 antibodies have a "Sera were those taken on day 42 in the experiment reported in Table 7 .
b Mean number of B. abortus in spleens of the control group was 245 x 104. ' Slope values from kinetics-based ELISA with 0 glycolipid as the antigen. Titers were estimated from slopes (Fig. 1). INFECT. IMMUN.
on October 19, 2017 by guest http://iai.asm.org/ Downloaded from critical role in protective immunity. A more critical test of this hypothesis would be to determine the correlation between antibody titers just prior to challenge and protection. Moreover, the resolution of this question will require not only quantitative measurements but also comparisons of isotype distribution and functional assessments of 0 antibodies from mice exhibiting different levels of immunity.
There is growing evidence that porins or other outer membrane proteins will prove to be useful as vaccines capable of inducing protective antibodies against Neisseria meningitidis (7, 17) , Pseudomonas aeruginosa (18, 30) , and Haemophilus influenzae (19, 27) . A protective role of porin antibodies against S. typhimurium has been proposed in several studies (4, 24, 49). Although some workers have now concluded that protection against S. typhimurium attributed to porin antibodies was due to 0 antibodies (41), the issue remains unresolved (49) . Data reported here offer no evidence for the participation of porin antibodies in protection against B. abortus. The antibody response of mice to porin was almost negligible, even when porin vaccines lacked OPS (Table 7 ). The protection produced in mice following two vaccinations with porin from rough strain RB51 was almost certainly due to 0 antibodies. The data indicate that two inoculations of this vaccine primed the mice to produce an accelerated 0 antibody response to the challenge infection (Tables 7 and 9 ). It cannot be excluded that somne of the antibodies reactive with f6 or 0 glycolipid were directed at core determinants. However, the marginal reactivity of these sera with porin-R-LPS (Table 7) indicates that the majority of antibodies were specific for OPS. Priming could have been a response to the porin and to trace quantities of OPS in the LPS of the rough strain or, in the absence of S-LPS, to the porin carrier alone. Whereas antibodies specific for porin and the group 3 outer membrane protein of B. abortus can be induced in cattle vaccinated with a rough strain of B. abortus such as 45/20 in TDM and MDP adjuvants (53, 55) , experimental infection with smooth virulent strains fails to evoke an appreciable increase in outer membrane protein-specific antibodies in cattle (C. L. Baldwin, Ph.D. thesis, Cornell University, Ithaca, 1983) or mice ( Table 7) . This suggests that in the cell envelope of B. abortus, epitopes of OPS are strongly dominant over those of the associated outer membrane proteins. Moreover, the failure of monoclonal antibodies specific for the porin of B. abortus to protect mice (32) and of polyvalent antisera specific for porin or group 3 antibodies to agglutinate smooth whole B. abortus cells (A. J. Winter, unpublished data) suggest that, as in the members of the family Enterobacteriaceae (50) , the outer membrane proteins of B. abortus
